logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Regeneron Pharmaceuticals, Inc. drugs

    FiltersReset Filters
    7 results

    • evkeeza

      (evinacumab)
      Regeneron Pharmaceuticals, Inc.
      Usage: EVKEEZA is indicated as an adjunct therapy for adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH). Its safety and effectiveness in other types of hypercholesterolemia, such as heterozygous familial hypercholesterolemia, have not been established.

    • eylea

      (aflibercept)
      Regeneron Pharmaceuticals, Inc.
      Usage: EYLEA is indicated for treating neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and retinopathy of prematurity.

    • inmazeb

      (atoltivimab, maftivimab, and odesivimab-ebgn)
      Regeneron Pharmaceuticals, Inc.
      Usage: INMAZEB is indicated for treating infections caused by *Orthoebolavirus zairense* in adults and pediatric patients, including neonates born to RT-PCR positive mothers. Its efficacy against other *Orthoebolavirus* species and *Orthomarburgvirus* has not been established. Consider drug susceptibility patterns when using INMAZEB.

    • libtayo

      (cemiplimab-rwlc)
      Regeneron Pharmaceuticals, Inc.
      Usage: LIBTAYO is indicated for treating metastatic or locally advanced cutaneous squamous cell carcinoma in patients unfit for curative surgery/radiation, locally advanced/metastatic basal cell carcinoma following previous hedgehog inhibitor treatment, and for first-line treatment of non-small cell lung cancer in specific adult patients.

    • lynozyfic - linvoseltamab - gcpt injection, solution, concentrate

      (Linvoseltamab-Gcpt)
      Regeneron Pharmaceuticals, Inc.

    • praluent

      (alirocumab)
      Regeneron Pharmaceuticals, Inc.
      Usage: PRALUENT® is indicated to reduce the risk of myocardial infarction, stroke, and unstable angina in adults with cardiovascular disease. It also lowers LDL-C in adults with primary hyperlipidemia or familial hypercholesterolemia and in pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia.

    • veopoz

      (Pozelimab)
      Regeneron Pharmaceuticals, Inc.
      Usage: VEOPOZ is indicated for treating adult and pediatric patients aged 1 year and older with CD55-deficient protein-losing enteropathy (PLE), also referred to as CHAPLE disease.